Aims & Scope
mAbs is a multi-disciplinary journal dedicated to the art and science of antibody research and development.
The journal has a strong scientific and medical focus, but also strives to serve a broader readership.
The articles are thus of interest to scientists, clinical researchers, and physicians, as well as the wider mAb community, including our readers involved in technology transfer, legal issues, investment, strategic planning and the regulation of therapeutics.
Relevant topics include (but are not be limited to): Antibody engineering and selection Targets relevant to cancer, immune-mediated disorders, and other diseases Non-clinical studies of antibodies, e.g., mechanism of action studies, safety and efficacy studies in animals Manufacturing Clinical studies Regulatory review of antibody therapeutics Post-approval topics, e.g., pricing, reimbursement and markets Patents Emerging markets for antibody therapeutics, including China and India All submitted manuscripts are subjected to initial evaluation by the editorial staff, and, if found suitable for further consideration, manuscripts are sent to peer review by independent, anonymous expert referees.
View Aims & ScopeMetrics & Ranking
Impact Factor
Year | Value |
---|---|
2025 | 7.3 |
2024 | 5.60 |
Journal Rank
Year | Value |
---|---|
2024 | 855 |
Journal Citation Indicator
Year | Value |
---|---|
2024 | 1956 |
SJR (SCImago Journal Rank)
Year | Value |
---|---|
2024 | 2.699 |
Quartile
Year | Value |
---|---|
2024 | Q1 |
h-index
Year | Value |
---|---|
2024 | 111 |
Impact Factor Trend
Abstracting & Indexing
Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.
Subjects & Keywords
Journal’s research areas, covering key disciplines and specialized sub-topics in Immunology and Microbiology and Medicine, designed to support cutting-edge academic discovery.
Licensing & Copyright
This journal operates under an Open Access model. Articles are freely accessible to the public immediately upon publication. The content is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0), allowing users to share and adapt the work with proper attribution.
Copyright remains with the author(s), and no permission is required for non-commercial use, provided the original source is cited.
Policy Links
This section provides access to essential policy documents, guidelines, and resources related to the journal’s publication and submission processes.
- Aims scope
- Homepage
- Oa statement
- Author instructions
- License terms
- Review url
- Board url
- Copyright url
- Plagiarism url
- Preservation url
- Apc url
- License
Plagiarism Policy
This journal follows a plagiarism policy. All submitted manuscripts are screened using reliable plagiarism detection software to ensure originality and academic integrity. Authors are responsible for proper citation and acknowledgment of all sources, and any form of plagiarism, including self-plagiarism, will not be tolerated.
For more details, please refer to our official: Plagiarism Policy.
APC Details
The journal’s Article Processing Charge (APC) policies support open access publishing in Immunology and Microbiology and Medicine, ensuring accessibility and quality in research dissemination.
This journal requires an Article Processing Charge (APC) to support open access publishing, covering peer review, editing, and distribution. The current APC is 6,110.00 AUD. Learn more.
Explore journals without APCs for alternative publishing options.